XML 81 R50.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Segments (Tables)

12 Months Ended

Dec. 31, 2019

Summary of Segment Profit

a. Segment information:

		Year ended December 31,
		2019
		North America				Europe				International Markets*
		(U.S. $ in millions)
Revenues		$	8,542			$	4,795			$	2,246
Gross profit			4,350				2,704				1,167
R&D expenses			652				262				88
S&M expenses			1,021				890				481
G&A expenses			439				239				138
Other income			(14	)			(5	)			(3	)
Segment profit		$	2,252			$	1,318			$	464
		Year ended December 31,
		2018
		North America				Europe				International Markets*
		(U.S. $ in millions)
Revenues		$	9,297			$	5,186			$	2,422
Gross profit			4,979				2,884				1,254
R&D expenses			713				283				96
S&M expenses			1,154				1,003				518
G&A expenses			484				325				153
Other income			(209	)			—				(11	)
Segment profit		$	2,837			$	1,273			$	498

		Year ended December 31,
		2017
		North America				Europe				International Markets*
		(U.S. $ in millions)
Revenues		$	12,141			$	5,466			$	2,863
Gross profit			7,322				2,887				1,433
R&D expenses			969				390				154
S&M expenses			1,288				1,130				672
G&A expenses			533				354				189
Other income			(92	)			(16	)			(8	)
Segment profit		$	4,624			$	1,029			$	426

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1b.

Schedule Of Consolidated Income Before Income Tax

		Year ended
		December 31,
		2019				2018				2017
		(U.S. $ in millions)
North America profit		$	2,252			$	2,837			$	4,624
Europe profit			1,318				1,273				1,029
International Markets profit			464				498				426
Total reportable segments profit			4,034				4,608				6,079
Profit (loss) of other activities			108				115				(6	)
Total segments profit			4,142				4,723				6,073
Amounts not allocated to segments:
Amortization			1,113				1,166				1,444
Other asset impairments, restructuring and other items			423				987				1,836
Goodwill impairment			—				3,027				17,100
Intangible asset impairments			1,639				1,991				3,238
Gain on divestitures, net of divestitures related costs			(50	)			(66	)			(1,083	)
Inventory Step—up			—				—				67
Other R&D expenses			(15	)			83				221
Costs related to regulatory actions taken in facilities			45				14				47
Legal settlements and loss contingencies			1,178				(1,208	)			500
Other unallocated amounts			252				366				187
Consolidated operating income (loss)			(443	)			(1,637	)			(17,484	)
Financial expenses, net			822				959				895
Consolidated income (loss) before income taxes		$	(1,265	)		$	(2,596	)		$	(18,379	)

Schedule of Net Sales by Product Line

North America segment:

		Year ended December 31,
		2019				2018				2017
		(U.S. $ in millions)
Generic products		$	3,963			$	4,056			$	5,203
COPAXONE			1,017				1,759				3,116
BENDEKA/TREANDA			496				642				656
ProAir*			274				397				501
QVAR			250				182				313
AJOVY			93				3				—
AUSTEDO			412				204				24
Anda			1,492				1,347				1,153
Other			546				708				1,175
Total		$	8,542			$	9,297			$	12,141

* Does not include revenues from the ProAir authorized generic, which are included under generic products.

Europe segment:

		Year ended December 31,
		2019				2018					2017
		(U.S. $ in millions)
Generic products		$	3,470			$	3,593			$	3,471
COPAXONE			432				535				595
Respiratory products			354				402				368
Other			539				656				1,033
Total		$	4,795			$	5,186			$	5,466

International Markets segment:

		Year ended December 31,
		2019				2018				2017
		(U.S. $ in millions)
Generic products		$	1,893			$	2,022			$	2,370
COPAXONE			63				72				91
Distribution			20				19				17
Other			271				309				385
Total		$	2,246			$	2,422			$	2,863

* The data presented for prior periods have been revised to reflect a revision in the presentation of net revenues and cost of sales in the consolidated financial statements. See note 1b.

Schedule of Sales Percentage by Therapeutic Category

The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2019, 2018 and 2017.

		Percentage of Third Party Net Sales
		2019				2018				2017
McKesson Corporation			13	%			12	%			16	%
AmerisourceBergen Corporation			12	%			14	%			15	%

Schedule of Property, Plant and Equipment by Geographic Location

d. Property, plant and equipment—by geographical location were as follows:

		December 31,
		2019				2018
		(U.S. $ in millions)
Israel		$	1,670			$	1,987
United States			864				950
Croatia			517				538
Germany			665				518
Czech republic			343				352
Hungary			330				343
Japan			177				188
Other			1,870				1,992
Total property, plant and equipment		$	6,436			$	6,868

X

- Definition

A schedule indicating where long-lived tangible assets are located.

+ References

No definition available.

+ Details

Name:	teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

A schedule of net sales by therapeutic category, stated as a percentage of total sales.

+ References

No definition available.

+ Details

Name:	teva_SalesPercentageByTherapeuticCategoryTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration